Changes are afoot to meet higher caseloads amid rising demand, the survey of 6,830 cardiovascular providers suggests.

Bioadaptor was designed to restore normal vessel function and reduce late stent-related complications. It’s working so far.

The national coverage determination explicitly outlines patient, clinician, and facilities criteria for qualifying procedures ...

Modern is consistent with the literature in this space, but the trial shows that a staged complete procedure might be just ...

Having more-thorough workup uncovered an unexpected root cause and changed the treatment course for 76% of patients.

The intracoronary fibrinolysis infusion joins a host of other failed treatments to improve microvascular obstruction after ...

The saphenous vein grafts treated in the RCT were relatively straightforward, while the native vessels were largely CTOs.

The DCB is meant to address long-term stent-related complications and avoid adding yet another metal layer in ISR.

The device, which is delivered transapically, represents an option for very sick patients who previously have had none.

The data are largely in line with those seen at 5 years, but the follow-up reassures there’s no concern about valve ...

TCTMD ® is produced by the Cardiovascular Research Foundation ® (CRF). CRF ® is committed to igniting the next wave of ...

Bioadaptor was designed to restore normal vessel function and reduce late stent-related complications. It’s working so far.